Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EKF DIAGNOSTICS HOLDINGS PLC AGM Information 2019

May 2, 2019

7617_dva_2019-05-02_c7babad6-6fc9-4040-a596-1cfa8603b442.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9062X

EKF Diagnostics Holdings PLC

02 May 2019

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Result of AGM

EKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nomad & Broker) Tel: 020 7496 3000
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)
Walbrook PR Limited                                                                           Tel: 020 7933 8780 or [email protected]
Paul McManus/ Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGSSAFSEFUSEFI